Menu
X

CAR T-Cell Therapy In China – Recent Advances

August 2023: Cancer patients who previously had few options now have hope because to CAR-T cell therapy, which has revolutionized the area of cancer treatment. With several clinical trials being conducted to increase the efficacy and safety of CAR-T cell therapy, China has emerged as a leader in this ground-breaking sector. These studies demonstrate the nation’s dedication to improving medical research and offering patients cutting-edge care. Currently there are more than 250 ongoing clinical trials on CAR T Cell therapy in China.

 

61126
As of January 30, 2018, China registered 171 CAR-T clinical research projects on ClinicalTrial.gov, which has surpassed Europe in number and is second only to the United States, and shows an increasing trend year by year.

What is the scope of CAR-T Cell Therapy in China?

 

The use of chimeric antigen receptor (CAR) T-cell treatments in the treatment of hematological malignancies has been incredibly effective. The application of CAR T-cell treatments has grown in China over the past nine years.

The first CAR T cell clinical studies started in 2013, and by 2017 there were more CAR T cell clinical trials than ever before. Soon after, China announced that it would provide a total of US$237 billion in funding for cell therapy businesses in 2021, which represented a huge increase in the number of clinical trials and fundamental research projects involving CAR T cells.

Strong government support, money inflow, high patient demand, a distinctive healthcare system, and the efforts of Chinese doctors and scientists all contributed to this significant surge in activity in China.

Why choose China for CAR T-Cell therapy?

Clinical trials and advance research

With more 350 ongoing clinical trials on CAR T-Cell therapy, China has achieved great strides. Innovative CAR T-cell therapies have been actively developed and tested by Chinese researchers and medical institutes, with a focus on both solid tumours and haematological malignancies. In terms of CAR T cell therapy developments, China has been in the vanguard, and there are numerous cutting-edge clinical trials happening there. Because of this, patients looking to access the most recent developments in CAR T cell therapy may find China to be an appealing alternative..

Cost and availability

CAR T-Cell therapy cost in China is significantly lower than that in countries like US, UK, Australia, Japan, Korea and Singapore. CAR T-Cell therapy in China may cost just $ 60,000 USD. China has a comparatively high availability of CAR T cell therapy. There may be shorter treatment wait periods now that more medical facilities in China have received regulatory authorization to provide CAR T cell therapy. In addition, CAR T cell therapy is frequently less expensive in China than it is in other places, like the United States. This element may be especially important for people looking for affordable treatment choices.

Expertise and experience

Due to its participation in multiple clinical trials and therapies, China has developed a significant amount of knowledge and experience in providing CAR T cell therapy. Chinese medical experts have improved their knowledge of CAR T cell therapy-related problems and their ability to manage them in order to improve patient outcomes. China offers high-quality healthcare thanks to its vast patient population, supportive infrastructure, and collected knowledge in CAR T cell therapy.

Companies in US collaborating with Chinese companies

In recent years, American businesses have begun collaborating with their Chinese counterparts to develop CAR T cell medicines. For ex. In 2015, WuXi AppTec, a Chinese contract research organisation (CRO), and Juno Therapeutics, a US-based biopharmaceutical business, partnered strategically. Chinese biopharmaceutical company Cellular Biomedicine Group worked with US biopharmaceutical company Celgene, which is now a division of Bristol-Myers Squibb. A global partnership and licence deal was made between Janssen Biotech, a pharmaceutical firm owned by Johnson & Johnson, and Legend Biotech, a business with operations in both China and the US.

CAR-T products have been marketed worldwide

                                               
Listed country Drug name Price Target point Time to market Research and development company indication
China Inaticabtagene Autoleucel(CNCT19)$136,111 CD19 2023.11 Juventas the treatment of adult B-cell relapsed and refractory acute lymphoblastic leukemia (B-ALL).
Equecabtagene Autoleucel(FUCASO)$160,308 BCMA 2023.7 IASO BioTherapeutics relapsed or refractory multiple myeloma who previously received 3 or more lines of therapy.
Axicabtagene ciloleucel(yescarta)$164,983 CD19 2021.6 Fosun Kite adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Relmacabtagene Autoleucel(Carteyva)$177,356 CD19 2022.10 JW Therapeutics the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL).
America Abecma $438,000 BCMA 2021.3 BristolMyers Squibb Treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.
Carvykti $465,000 BCMA 2022.2 Legend Biotech the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
Breyanzi $410,300 CD19 2021.2 BristolMyers Squibb to treat adult patients with certain types of large B-cell lymphoma
Tecartus $373,000 CD19 2020.7 Gilead Sciences Relapsed or Refractory Mantle Cell Lymphoma
Yescarta $373,000 CD19 2017.10 Kite Pharma to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.
Kymriah $475,000 CD19 2017.8 Novartis for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).
  • The US FDA approved the market of CAR-T

  • CAR-T approved for market in China

                   
  • 1Whole-process management

    1.Disease analysis
    2. Create a file
    3. Sorting out medical records
    4. Preliminary assessment
    5. Consult and arrange living assistance
    6. Disease follow-up
    7. Get insurance

  • 2Expert consultation assessment

    1.Medical record collection
    2.Translation of medical records
    3.Text consultation
    4.Video consultation

  • 3Ground access service

    1. Apply for hospital invitation letter
    2. Apply for a visa
    3. Book a hotel
    4. Airport pick-up and transportation
    5. Mobile card processing
    6. Daily living assistance
    7. Daily travel booking and assistance

  • 4Medical service

    1. Designated hospitals are green
    2. Assist in arranging examinations, hospitalization and treatment
    3. Interpreter accompanied by hospital
    4. Assist in issuing bills

  • 5CAR-T therapy
    making a treatment plan

    1.CART cell technology Services

  • 6Family accommodation

    1. Based on 2 persons/month
    2. Provide accommodation assistance to overseas personnel

  • 1Whole-process management
    1.Disease analysis 2. Create a file 3. Sorting out medical records 4. Preliminary assessment 5. Consult and arrange living assistance 6. Disease follow-up 7. Get insurance
  • 2Expert consultation assessment
    1.Medical record collection 2.Translation of medical records 3.Text consultation 4.Video consultation
  • 3Ground access service
    1. Apply for hospital invitation letter 2. Apply for a visa 3. Book a hotel 4. Airport pick-up and transportation 5. Mobile card processing 6. Daily living assistance 7. Daily travel booking and assistance
  • 6Family accommodation
    1. Based on 2 persons/month 2. Provide accommodation assistance to overseas personnel
  • 5CAR-T therapy making a treatment plan
    1.CART cell technology Services
  • 4Medical service
    1. Designated hospitals are green 2. Assist in arranging examinations, hospitalization and treatment 3. Interpreter accompanied by hospital 4. Assist in issuing bills

Top hospitals for CAR T-Cell therapy in China

Expert Team

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.